CA2666842A1 - Antagonistes de l'il-17c et leurs procedes d'utilisation - Google Patents

Antagonistes de l'il-17c et leurs procedes d'utilisation Download PDF

Info

Publication number
CA2666842A1
CA2666842A1 CA002666842A CA2666842A CA2666842A1 CA 2666842 A1 CA2666842 A1 CA 2666842A1 CA 002666842 A CA002666842 A CA 002666842A CA 2666842 A CA2666842 A CA 2666842A CA 2666842 A1 CA2666842 A1 CA 2666842A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
soluble receptor
fragment
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666842A
Other languages
English (en)
Inventor
Mark W. Appleby
Mark W. Rixon
Kenneth B. Lewis
Zeren Gao
Rolf E. Kuestner
Carl W. Birks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666842A1 publication Critical patent/CA2666842A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des antagonistes de l'IL-17RE, tels que des récepteurs solubles et des anticorps anti-IL-17RE, qui se révèlent utiles pour bloquer, inhiber, réduire, produire des effets antagonistes ou neutraliser l'activité de l'IL-17C. L'IL-17C est une cytokine qui est impliquée dans des processus inflammatoires et des maladies humaines. L'IL-17RE est un récepteur de l'IL-17C. La présente invention concerne un IL-17RE soluble, un peptide de fusion soluble contenant un ou plusieurs anticorps anti-IL-17RE et partenaires de liaison des domaines de l'IL-17RE, ainsi que des procédés permettant de produire un effet antagoniste sur l'IL-17C au moyen de tels récepteurs solubles, anticorps et partenaires de liaison.
CA002666842A 2006-10-18 2007-10-18 Antagonistes de l'il-17c et leurs procedes d'utilisation Abandoned CA2666842A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US82997206P 2006-10-18 2006-10-18
US60/829,972 2006-10-18
US86463306P 2006-11-07 2006-11-07
US60/864,633 2006-11-07
US86789306P 2006-11-30 2006-11-30
US60/867,893 2006-11-30
US89077607P 2007-02-20 2007-02-20
US60/890,776 2007-02-20
US91740407P 2007-05-11 2007-05-11
US60/917,404 2007-05-11
PCT/US2007/081812 WO2008049070A2 (fr) 2006-10-18 2007-10-18 Antagonistes de l'il-17c et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
CA2666842A1 true CA2666842A1 (fr) 2008-04-24

Family

ID=39226684

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666842A Abandoned CA2666842A1 (fr) 2006-10-18 2007-10-18 Antagonistes de l'il-17c et leurs procedes d'utilisation

Country Status (3)

Country Link
EP (1) EP2064237A2 (fr)
CA (1) CA2666842A1 (fr)
WO (1) WO2008049070A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
PL2769729T3 (pl) 2007-09-04 2019-09-30 Compugen Ltd. Polipeptydy i polinukleotydy i ich zastosowanie jako cel dla leków do wytwarzania leków i środków biologicznych
HUE035618T2 (en) 2010-01-15 2018-05-28 Kirin Amgen Inc Antibody presentation and therapeutic regimens
EP2633317A1 (fr) * 2010-10-25 2013-09-04 Genentech, Inc. Traitement de l'inflammation gastro-intestinale et du parapsoriasis
WO2013001517A1 (fr) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides et leurs utilisations pour traiter les troubles auto-immuns et l'infection
US20140234330A1 (en) * 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
CN103974976A (zh) 2011-10-19 2014-08-06 莫佛塞斯公司 用于治疗炎性病症的il17c拮抗剂
JP2015512616A (ja) 2012-02-01 2015-04-30 コンピュゲン エルティーディー． Ｃ１ｏｒｆ３２抗体およびがんの治療のためのその使用
WO2013186236A1 (fr) * 2012-06-12 2013-12-19 Orega Biotech Antagonistes d'isoformes d'il-17 et leurs utilisations
EP2858670B8 (fr) * 2012-06-12 2018-09-12 Orega Biotech Antagonistes d'isoformes d'il-17 et leurs utilisations
KR20180058806A (ko) 2015-10-05 2018-06-01 모르포시스 아게 아토피 피부염의 치료 및/또는 예방을 위한 il-17c의 길항제
CN108699143B (zh) 2016-02-19 2021-11-09 莫佛塞斯公司 Il-17c的抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005295421A1 (en) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation
WO2007047738A1 (fr) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Antagonistes de il-17c et méthodes d'utilisation desdits antagonistes

Also Published As

Publication number Publication date
WO2008049070A2 (fr) 2008-04-24
WO2008049070A3 (fr) 2008-09-18
EP2064237A2 (fr) 2009-06-03
WO2008049070A9 (fr) 2008-07-10

Similar Documents

Publication Publication Date Title
AU2006294511B2 (en) IL-17A and IL-17F antagonists and methods of using the same
AU2005254998B2 (en) Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
AU2008230843B2 (en) Soluble IL-17RA/RC fusion proteins and related methods
US8093355B2 (en) Soluble IL-17RCx4 and fusion proteins thereof
US7842665B2 (en) IL-17A and IL-17F antagonists
CA2666842A1 (fr) Antagonistes de l'il-17c et leurs procedes d'utilisation
CA2624763A1 (fr) Antagonistes de il-17c et methodes d'utilisation desdits antagonistes
US20070049524A1 (en) Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20111018